Article

OccuLogix completes SOLX acquisition

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Based at the Boston University Photonics Center, SOLX developed the DeepLight Glaucoma Treatment System, including the DeepLight 790 Titanium Sapphire Laser and the DeepLight Gold Micro-Shunt, which can be used together or separately to reduce IOP. The system components have received international CE approval and are being studied in two randomized, multicenter trials in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.